Table 1 Patient characteristics.
| HC | PR3‐ANCA | MPO‐ANCA | RA | SLE | |
|---|---|---|---|---|---|
| Number | 25 | 25 | 14 | 25 | 25 |
| Gender | |||||
| Male | 15 | 20 | 5 | 7 | 4 |
| Female | 10 | 5 | 9 | 18 | 21 |
| Mean age (years) | 42±9 | 59±16 | 53±18 | 50±13 | 49±14 |
| Inactive disease | — | 24(96%) | 12(93%) | 15(60%) | 24(96%) |
| Treatment at the time of testing: | |||||
| CP, AZA, MTX or MMF | — | 12(48%) | 5(38%) | 18(72%) | 9(36%) |
| Prednisolone | — | 7(28%) | 5(38%) | 1(4%) | 10(40%) |
HC, healthy control; PR‐ANCA, PR3‐ANCA‐associated vasculitis; MPO‐ANCA, MPO‐ANCA‐associated vasculitis; RA, rheumatoid arthritis; SLE, systemic lupus erythematosus; CP, cyclophosphamide; AZA, azathioprine; MTX, methotrexate; MMF, mycophenolate mofetil.